Galecto Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
GLTO Nasdaq 8731 https://galecto.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galecto Inc

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022 - Mar 9th, 2023 12:00 pm
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference - Mar 2nd, 2023 9:05 pm
Galecto to Participate in SVB Securities Global Biopharma Conference - Feb 1st, 2023 1:00 pm
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth? - Dec 11th, 2022 12:36 pm
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting - Dec 7th, 2022 9:05 pm
Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nov 24th, 2022 2:55 pm
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy - Nov 11th, 2022 5:00 pm
Galecto Reports Third Quarter Operating and Financial Results - Nov 8th, 2022 2:15 pm
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients - Nov 8th, 2022 11:00 am
Galecto to Participate in Jefferies London Healthcare Conference - Nov 3rd, 2022 12:00 pm
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022 - Oct 31st, 2022 12:00 pm
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute - Oct 19th, 2022 12:00 pm
Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022 - Oct 17th, 2022 10:00 am
Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis - Sep 29th, 2022 3:17 pm
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target - Sep 29th, 2022 10:00 am
Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 12:30 pm
Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal - Aug 29th, 2022 12:30 pm
Galecto Reports Second Quarter Operating and Financial Results - Jul 29th, 2022 1:00 pm
Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely? - Jul 3rd, 2022 12:17 pm
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC - Jun 16th, 2022 12:00 pm